2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy

OBJECTIVES/SPECIFIC AIMS: Preliminary animal studies showed that low-intensity ultrasound (US) coincident with intravascularly administered microbubbles locally disrupts tumor vasculature. This study translates the novel therapy of antivascular ultrasound (AVUS) into an autochthonous model of hepato...

Full description

Bibliographic Details
Main Authors: Julia D’Souza, Laith Sultan, Sean Carlin, Terence Gade, Stephen Hunt, Chandra Sehgal
Format: Article
Language:English
Published: Cambridge University Press 2018-06-01
Series:Journal of Clinical and Translational Science
Online Access:https://www.cambridge.org/core/product/identifier/S205986611800050X/type/journal_article
_version_ 1811156702104387584
author Julia D’Souza
Laith Sultan
Sean Carlin
Terence Gade
Stephen Hunt
Chandra Sehgal
author_facet Julia D’Souza
Laith Sultan
Sean Carlin
Terence Gade
Stephen Hunt
Chandra Sehgal
author_sort Julia D’Souza
collection DOAJ
description OBJECTIVES/SPECIFIC AIMS: Preliminary animal studies showed that low-intensity ultrasound (US) coincident with intravascularly administered microbubbles locally disrupts tumor vasculature. This study translates the novel therapy of antivascular ultrasound (AVUS) into an autochthonous model of hepatocellular carcinoma (HCC). The differential effects produced by AVUS at low and high doses are evaluated. METHODS/STUDY POPULATION: HCC was induced in 12 Wistar rats by ingestion of 0.01% diethylnitrosamine in drinking water for 12 weeks. Rats received AVUS treatment at low and high doses. Low dose group (n=6) received 1 W/cm2 US for 1 minute with 0.2 mL microbubbles injected IV. High dose group (n=6) received 2 W/cm2 for 2 minute with 0.7 mL microbubbles IV. Perfusion was measured before and after AVUS with contrast-enhanced ultrasound (CE-US) and power Doppler (PD-US). Peak enhancement (PE) and perfusion index (PI) were measured from each US mode. Histology after sacrifice or natural death was compared to pre/post US. Analysis of H&E and trichrome sections was evaluated for percent area of hemorrhage and findings of tissue injury and repair including inflammation, necrosis, and fibrosis. RESULTS/ANTICIPATED RESULTS: After high dose AVUS, PE, and PI of CE-US decreased from baseline by an average of 33.3% and 29.7%, respectively. Histology showed extensive tissue injury (hemorrhage, necrosis, fibrosis) in 58% of tumor cross-sectional area. Conversely, low dose AVUS increased PE and PI of CE-US by an average of 39.3% and 67.8%, respectively. Histology showed smaller areas of microhemorrhage Versus large pools of hemorrhage (only 17% area). PD-US changes were similar to CE-US. DISCUSSION/SIGNIFICANCE OF IMPACT: In summary, the opposing effects of AVUS observed at 2 doses allows for multiple roles in tumor therapy. Enhanced perfusion at a low dose may improve drug delivery or radiation therapy. Whereas, vascular disruption at high doses of AVUS may allow noninvasive ischemic therapy. Furthermore, AVUS is ripe for translation given the use its component parts clinically: low-intensity long-tone burst for physiotherapy and microbubbles as an US contrast agent. Thus, AVUS should be evaluated for translation of its differential effects into noninvasive therapies for HCC and other tumors.
first_indexed 2024-04-10T04:55:53Z
format Article
id doaj.art-5b7e2025c2274e30bef5e520d3354f8a
institution Directory Open Access Journal
issn 2059-8661
language English
last_indexed 2024-04-10T04:55:53Z
publishDate 2018-06-01
publisher Cambridge University Press
record_format Article
series Journal of Clinical and Translational Science
spelling doaj.art-5b7e2025c2274e30bef5e520d3354f8a2023-03-09T12:30:17ZengCambridge University PressJournal of Clinical and Translational Science2059-86612018-06-0125610.1017/cts.2018.502167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapyJulia D’Souza0Laith Sultan1Sean Carlin2Terence Gade3Stephen Hunt4Chandra Sehgal5School of Medicine, University of PennsylvaniaSchool of Medicine, University of PennsylvaniaSchool of Medicine, University of PennsylvaniaSchool of Medicine, University of PennsylvaniaSchool of Medicine, University of PennsylvaniaSchool of Medicine, University of PennsylvaniaOBJECTIVES/SPECIFIC AIMS: Preliminary animal studies showed that low-intensity ultrasound (US) coincident with intravascularly administered microbubbles locally disrupts tumor vasculature. This study translates the novel therapy of antivascular ultrasound (AVUS) into an autochthonous model of hepatocellular carcinoma (HCC). The differential effects produced by AVUS at low and high doses are evaluated. METHODS/STUDY POPULATION: HCC was induced in 12 Wistar rats by ingestion of 0.01% diethylnitrosamine in drinking water for 12 weeks. Rats received AVUS treatment at low and high doses. Low dose group (n=6) received 1 W/cm2 US for 1 minute with 0.2 mL microbubbles injected IV. High dose group (n=6) received 2 W/cm2 for 2 minute with 0.7 mL microbubbles IV. Perfusion was measured before and after AVUS with contrast-enhanced ultrasound (CE-US) and power Doppler (PD-US). Peak enhancement (PE) and perfusion index (PI) were measured from each US mode. Histology after sacrifice or natural death was compared to pre/post US. Analysis of H&E and trichrome sections was evaluated for percent area of hemorrhage and findings of tissue injury and repair including inflammation, necrosis, and fibrosis. RESULTS/ANTICIPATED RESULTS: After high dose AVUS, PE, and PI of CE-US decreased from baseline by an average of 33.3% and 29.7%, respectively. Histology showed extensive tissue injury (hemorrhage, necrosis, fibrosis) in 58% of tumor cross-sectional area. Conversely, low dose AVUS increased PE and PI of CE-US by an average of 39.3% and 67.8%, respectively. Histology showed smaller areas of microhemorrhage Versus large pools of hemorrhage (only 17% area). PD-US changes were similar to CE-US. DISCUSSION/SIGNIFICANCE OF IMPACT: In summary, the opposing effects of AVUS observed at 2 doses allows for multiple roles in tumor therapy. Enhanced perfusion at a low dose may improve drug delivery or radiation therapy. Whereas, vascular disruption at high doses of AVUS may allow noninvasive ischemic therapy. Furthermore, AVUS is ripe for translation given the use its component parts clinically: low-intensity long-tone burst for physiotherapy and microbubbles as an US contrast agent. Thus, AVUS should be evaluated for translation of its differential effects into noninvasive therapies for HCC and other tumors.https://www.cambridge.org/core/product/identifier/S205986611800050X/type/journal_article
spellingShingle Julia D’Souza
Laith Sultan
Sean Carlin
Terence Gade
Stephen Hunt
Chandra Sehgal
2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy
Journal of Clinical and Translational Science
title 2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy
title_full 2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy
title_fullStr 2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy
title_full_unstemmed 2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy
title_short 2167 Beyond diagnosis: Using ultrasound to affect tumor vasculature for hepatocellular carcinoma (HCC) therapy
title_sort 2167 beyond diagnosis using ultrasound to affect tumor vasculature for hepatocellular carcinoma hcc therapy
url https://www.cambridge.org/core/product/identifier/S205986611800050X/type/journal_article
work_keys_str_mv AT juliadsouza 2167beyonddiagnosisusingultrasoundtoaffecttumorvasculatureforhepatocellularcarcinomahcctherapy
AT laithsultan 2167beyonddiagnosisusingultrasoundtoaffecttumorvasculatureforhepatocellularcarcinomahcctherapy
AT seancarlin 2167beyonddiagnosisusingultrasoundtoaffecttumorvasculatureforhepatocellularcarcinomahcctherapy
AT terencegade 2167beyonddiagnosisusingultrasoundtoaffecttumorvasculatureforhepatocellularcarcinomahcctherapy
AT stephenhunt 2167beyonddiagnosisusingultrasoundtoaffecttumorvasculatureforhepatocellularcarcinomahcctherapy
AT chandrasehgal 2167beyonddiagnosisusingultrasoundtoaffecttumorvasculatureforhepatocellularcarcinomahcctherapy